Approximately one in 200 U.S. babies is born with congenital CMV infection, according to CDC.
Congenital CMV Awareness Month 2026: Connect Prevention, Detection, and Early Support
- Posted by Greg Wahlstrom, MBA, HCM
- Posted in 2026 Healthcare Observances Calendar, Health Observance Calendar
Skip to the executive brief
1 in 200
1 in 5
Time-sensitive
Stage 01
Stage 02
Stage 03
Stage 04
Stage 05
Executive Maternal and Infant Health Operating Brief
Congenital CMV Awareness Month 2026: Connect Prevention, Detection, and Early Support
Use June to strengthen practical prevention education, time-sensitive newborn testing, hearing surveillance, developmental follow-up, family support, and accountable care coordination.
The leadership signal: a narrow testing window requires a reliable system
Congress designated June as National CMV Awareness Month to increase understanding of cytomegalovirus and congenital CMV. CMV is common and usually causes mild or no symptoms in healthy people. When infection occurs during pregnancy, however, the virus can pass to the developing fetus. Congenital CMV can affect hearing, vision, the brain, growth, and development, although many infants appear healthy at birth.
The Centers for Disease Control and Prevention reports that about one in 200 babies is born with congenital CMV infection. About one in five babies with congenital CMV will have birth defects or other long-term health problems. Those figures justify serious attention, but not fear-based communication. Leaders should give families practical prevention information, accurate testing pathways, clear interpretation, and compassionate support.
The central operating issue is time. Testing that confirms congenital infection must use appropriate specimens collected within the first weeks of life so clinicians can distinguish congenital from later-acquired CMV. A failed hearing screen, concerning prenatal or newborn findings, or another state or organizational criterion must trigger a defined action. If ownership is unclear, the opportunity for timely confirmation, evaluation, treatment consideration, and baseline assessment can close.
Three facts that should shape the 2026 response
About one in five babies with congenital CMV develops birth defects or other long-term health problems.
Diagnosis depends on appropriate testing early in life, followed by reliable confirmatory and specialty processes.
Congenital CMV is not always visible at birth. Some infants have signs that prompt immediate evaluation. Others may later develop sensorineural hearing loss or developmental concerns. A normal newborn appearance or an initial hearing result does not eliminate every future risk. Follow-up should be based on current clinical guidance and the infant’s findings, not a single generic schedule.
Prevention communication should stay practical. CMV spreads through body fluids, including saliva and urine. Pregnant people who have frequent contact with young children can reduce exposure by washing hands after changing diapers or helping with toileting, and by avoiding sharing food, cups, utensils, or pacifiers. Organizations should teach these behaviors without implying that a parent caused an infection.
Build one connected route from pregnancy through early childhood
A reliable pathway makes the next step visible at every transition. Prenatal teams provide prevention education and document relevant concerns. Newborn services apply defined testing criteria. Laboratories use the correct specimen, method, and turnaround expectations. Pediatric and specialty teams interpret results, assess organ involvement, discuss treatment when indicated, and establish hearing, vision, neurological, developmental, and primary-care follow-up.
Prevent
Offer practical hygiene education without blame or alarm.
Recognize
Identify newborn, prenatal, hearing, or clinical triggers.
Confirm
Complete appropriate testing within the diagnostic window.
Assess
Coordinate clinical, hearing, vision, imaging, and laboratory review.
Support
Connect treatment, surveillance, early intervention, and family navigation.
Targeted and universal screening policies differ across jurisdictions and continue to evolve. Health systems should follow current federal, state, and professional guidance, define which policy they use, and monitor equity and missed opportunities. Awareness messaging must not imply that every infant follows the same testing or treatment plan.
Six executive decisions that turn awareness into reliable care
1. Standardize prenatal prevention education
Embed plain-language CMV education into prenatal workflows, patient portals, childbirth classes, and pediatric anticipatory guidance. Use qualified interpreters and accessible formats. Teach realistic exposure-reduction behaviors while avoiding stigma, blame, or an impossible promise of zero risk.
2. Define newborn testing triggers and ownership
Publish criteria for testing, specimen collection, confirmatory steps, documentation, and result ownership. Align newborn nursery, NICU, pediatrics, audiology, laboratory, obstetrics, infection prevention, and public health. Every result needs a named clinician responsible for communicating and acting.
3. Protect the diagnostic window
Track time from trigger to specimen and from result to family contact. Build weekend, holiday, transfer, and discharged-newborn procedures. A referral placed after discharge is not a closed loop. Escalate when specimen quality, turnaround, or family contact threatens timely diagnosis.
4. Coordinate treatment decisions
Infants with symptomatic congenital CMV may need prompt specialty assessment and consideration of antiviral treatment under current clinical guidance. Standardize infectious-disease consultation, baseline testing, medication access, laboratory monitoring, adverse-effect response, and shared decisions. Do not present treatment as appropriate for every infant.
5. Make hearing and development follow-up durable
Connect audiology, early hearing detection and intervention, vision, neurology, developmental services, primary care, and early intervention. Track completed care, not referrals alone. Give families one schedule, one contact, and a clear response when a milestone, hearing concern, or appointment is missed.
6. Measure equity and family burden
Review access by race, ethnicity, language, geography, insurance, transfer status, and NICU versus well-newborn setting. Monitor travel, appointment load, time away from work, interpreter access, and out-of-pocket burden. Co-design education and navigation with families who have lived experience.
Support the family without reducing the child to a diagnosis
A congenital CMV result can create uncertainty, grief, urgency, and information overload. Families need accurate counseling about what is known, what remains uncertain, which findings matter now, and what follow-up can accomplish. Avoid deterministic predictions. Many children with congenital CMV do well, while others need sustained clinical, educational, and family support.
Provide written and verbal plans, contact information, appointment coordination, financial navigation, and connection to early intervention or community resources. Ask permission before sharing information. Use person-first, culturally responsive language and respect the family’s goals. A strong care plan protects both clinical reliability and family agency.
Put congenital CMV reliability on the executive scorecard
| Domain | Core measure | Executive question |
|---|---|---|
| Education | Prenatal patients receiving accessible prevention information | Is education practical, available, and free of blame? |
| Recognition | Eligible newborns receiving indicated testing before the window closes | Where do triggers fail to become action? |
| Laboratory | Valid specimens, turnaround, confirmation, and result ownership | Can every result be traced to a responsible clinician? |
| Assessment | Timely specialty and baseline evaluation when indicated | Do transfers and weekends create delay? |
| Follow-up | Hearing and developmental surveillance completed to plan | Which children are lost after the newborn period? |
| Family experience | Understanding, navigation access, and burden reported by families | Does the system make the pathway manageable? |
| Equity | Testing, treatment, and follow-up stratified across populations | Who is least likely to receive timely care? |
Interpret measures together. More testing is not automatically better if criteria, consent, confirmation, counseling, and follow-up are weak. Low missed-appointment rates may conceal families who never entered the pathway. Pair operational data with chart review, family feedback, and public-health requirements.
A 90-day activation plan
Days 1 to 30: Map
- Name an executive sponsor and pathway owner.
- Map prenatal education, newborn triggers, testing, and follow-up.
- Audit specimen timing, results, transfers, and lost referrals.
- Listen to families and frontline teams.
Days 31 to 60: Test
- Run failed-hearing-screen, weekend-discharge, transfer, and language-access scenarios.
- Test result ownership and urgent escalation.
- Review treatment-monitoring and pharmacy access.
- Audit hearing and early-intervention handoffs.
Days 61 to 90: Scale
- Publish the testing and follow-up standard.
- Launch the dashboard with equity measures.
- Train maternal-child and ambulatory teams.
- Continue governance after June.
Conclusion: protect the window, then protect the follow-through
National CMV Awareness Month 2026 should move beyond recognition alone. Health systems can reduce avoidable delay by connecting prevention education, newborn triggers, correct testing, accountable results, appropriate specialty assessment, hearing surveillance, developmental support, and family navigation.
The executive mandate is concrete. Make ownership visible. Design for nights, weekends, transfers, language access, and families carrying many appointments. Measure completed care rather than orders placed. When the diagnostic window and the years of follow-up are both protected, awareness becomes a durable maternal and child health operating system.
Authoritative resources
Public health and clinical information
Clinical note: Testing, interpretation, treatment, and surveillance should follow current patient-specific guidance and applicable state requirements. Practice note: This executive brief supports operational planning and does not replace clinical judgment, informed consent, public-health direction, or emergency evaluation.
